Literature DB >> 27866217

Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) in an osteoporotic patient chronically treated with bisphosphonates.

A Sánchez1, R Blanco2.   

Abstract

The aim of the study is to report the rare association of two complications of long-term treatment of osteoporosis with bisphosphonates in the same Caucasian elderly patient. A female patient of Italian descent, age 87 years, consulted in February 2013. She had a history of osteoporosis and had taken alendronate weekly for 7 years (1999-2006). Due to low back pain, an orthopedist had indicated i.v. zoledronic acid, 5 mg/year for 3 years (2006-2008). She received occasional supplements of ergocalciferol. In 2009, she suffered a fall and sustained a subtrochanteric fracture of the left femur. She was operated on and recovered uneventfully. In 2012, she consulted a dentist due to loose teeth. She underwent the removal of a molar and was given a denture. She had discomfort when using the prosthesis, and developed an ulceration in the gum of the mandible, which exposed the bone and did not heal for 2 months. After radiologic studies, the diagnosis was osteonecrosis of the jaw. She improved after surgical debridement and local and systemic antibiotics. In early 2013, laboratory tests were normal except for a slight elevation of serum PTH and CTX-I. Calcitriol 0.25 mcg/day was prescribed; after 3 months serum calcium, phosphate, PTH, and CTX-I showed no variation. Two years later, she experienced acute low back pain after a fall; MRI showed recent crushing of D12, and chronic deformities of D11 and L1. Bone densitometry of her right hip (DXA) showed a T-score of -2.3 at the femoral neck. An X-ray film of the right femur showed diffuse thickening of both cortices. She was treated with nasal calcitonin and analgesics. After the back pain subsided, she was treated with s.c. denosumab. Although the association of ONJ and AFF was known in cancer patients treated with high doses of bisphosphonates, it is very rare in patients with osteoporosis receiving these drugs at usual doses. Only three cases have been reported, all in oriental women. This appears to be the first reported case in a Caucasian woman.

Entities:  

Keywords:  Bisphosphonates; Complications; Drug-induced osteonecrosis of the jaw; Osteoporosis; Subtrochanteric atypical fractures; Treatment

Mesh:

Substances:

Year:  2016        PMID: 27866217     DOI: 10.1007/s00198-016-3840-z

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  12 in total

1.  Gender related difference in the risk of bisphosphonate associated atypical femoral fracture and osteonecrosis of the jaw.

Authors:  Mohammad Kharazmi; Pär Hallberg; Karl Michaëlsson
Journal:  Ann Rheum Dis       Date:  2014-04-30       Impact factor: 19.103

Review 2.  Bisphosphonates--history and experimental basis.

Authors:  H Fleisch
Journal:  Bone       Date:  1987       Impact factor: 4.398

3.  Concurrent bisphosphonate-related bilateral atypical subtrochanteric fractures and osteonecrosis of the jaw on bone scintigraphy.

Authors:  Jo Eun Kim; Mijin Yun; Sung-Kil Lim; Yumie Rhee
Journal:  Clin Nucl Med       Date:  2015-05       Impact factor: 7.794

4.  Prolonged antiresorptive activity of zoledronate: a randomized, controlled trial.

Authors:  Andrew Grey; Mark Bolland; Diana Wattie; Anne Horne; Greg Gamble; Ian R Reid
Journal:  J Bone Miner Res       Date:  2010-10       Impact factor: 6.741

Review 5.  Pathophysiology of atypical femoral fractures and osteonecrosis of the jaw.

Authors:  J Compston
Journal:  Osteoporos Int       Date:  2011-10-14       Impact factor: 4.507

Review 6.  Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research.

Authors:  Elizabeth Shane; David Burr; Bo Abrahamsen; Robert A Adler; Thomas D Brown; Angela M Cheung; Felicia Cosman; Jeffrey R Curtis; Richard Dell; David W Dempster; Peter R Ebeling; Thomas A Einhorn; Harry K Genant; Piet Geusens; Klaus Klaushofer; Joseph M Lane; Fergus McKiernan; Ross McKinney; Alvin Ng; Jeri Nieves; Regis O'Keefe; Socrates Papapoulos; Tet Sen Howe; Marjolein C H van der Meulen; Robert S Weinstein; Michael P Whyte
Journal:  J Bone Miner Res       Date:  2013-10-01       Impact factor: 6.741

7.  Atypical femoral fractures shortly after osteonecrosis of the jaw in a postmenopausal woman taking alendronate for osteoporosis.

Authors:  Wei-Yih Chiu; Jang-Jaer Lee; Keh-Sung Tsai
Journal:  J Clin Endocrinol Metab       Date:  2013-03-07       Impact factor: 5.958

8.  Healing Time and Complications in Operatively Treated Atypical Femur Fractures Associated With Bisphosphonate Use: A Multicenter Retrospective Cohort.

Authors:  Yelena Bogdan; Paul Tornetta; Thomas A Einhorn; Pierre Guy; Lise Leveille; Juan Robinson; Michael J Bosse; Nikkole Haines; Daniel Horwitz; Clifford Jones; Emil Schemitsch; Claude Sagi; Bryan Thomas; Daniel Stahl; William Ricci; Megan Brady; David Sanders; Michael Kain; Thomas F Higgins; Cory Collinge; Stephen Kottmeier; Darin Friess
Journal:  J Orthop Trauma       Date:  2016-04       Impact factor: 2.512

Review 9.  Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.

Authors:  Aliya A Khan; Archie Morrison; David A Hanley; Dieter Felsenberg; Laurie K McCauley; Felice O'Ryan; Ian R Reid; Salvatore L Ruggiero; Akira Taguchi; Sotirios Tetradis; Nelson B Watts; Maria Luisa Brandi; Edmund Peters; Teresa Guise; Richard Eastell; Angela M Cheung; Suzanne N Morin; Basel Masri; Cyrus Cooper; Sarah L Morgan; Barbara Obermayer-Pietsch; Bente L Langdahl; Rana Al Dabagh; K Shawn Davison; David L Kendler; George K Sándor; Robert G Josse; Mohit Bhandari; Mohamed El Rabbany; Dominique D Pierroz; Riad Sulimani; Deborah P Saunders; Jacques P Brown; Juliet Compston
Journal:  J Bone Miner Res       Date:  2015-01       Impact factor: 6.741

10.  American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; John Fantasia; Reginald Goodday; Tara Aghaloo; Bhoomi Mehrotra; Felice O'Ryan
Journal:  J Oral Maxillofac Surg       Date:  2014-05-05       Impact factor: 2.136

View more
  6 in total

1.  Treatment of Medication-Related Osteonecrosis of the Jaw and its Impact on a Patient's Quality of Life: A Single-Center, 10-Year Experience from Southern Italy.

Authors:  Giacomo Oteri; Gianluca Trifirò; Matteo Peditto; Loredana Lo Presti; Ilaria Marcianò; Francesco Giorgianni; Janet Sultana; Antonia Marcianò
Journal:  Drug Saf       Date:  2018-01       Impact factor: 5.606

2.  Osteonecrosis of the Jaw (ONJ) in Osteoporosis Patients: Report of Delayed Diagnosis of a Multisite Case and Commentary about Risks Coming from a Restricted ONJ Definition.

Authors:  Mario Migliario; Giovanni Mergoni; Paolo Vescovi; Iolanda De Martino; Manuela Alessio; Luca Benzi; Filippo Renò; Vittorio Fusco
Journal:  Dent J (Basel)       Date:  2017-03-16

3.  Osteonecrosis of the Jaw and Bilateral Atypical Femoral Fracture Both Occurring During Treatment for Osteoporosis: A Case Report.

Authors:  Edelissa Payumo; Beinjerinck Ivan Cudal; Thelma Crisostomo
Journal:  J ASEAN Fed Endocr Soc       Date:  2018-09-12

4.  Resistant Starch Attenuates Bone Loss in Ovariectomised Mice by Regulating the Intestinal Microbiota and Bone-Marrow Inflammation.

Authors:  Yuko Tousen; Yu Matsumoto; Yuya Nagahata; Isao Kobayashi; Masahiro Inoue; Yoshiko Ishimi
Journal:  Nutrients       Date:  2019-01-30       Impact factor: 5.717

5.  Exploring the Mechanisms Underlying Drug-Induced Fractures Using the Japanese Adverse Drug Event Reporting Database.

Authors:  Shinya Toriumi; Akinobu Kobayashi; Hitoshi Sueki; Munehiro Yamamoto; Yoshihiro Uesawa
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-13

6.  The Effect of Bisphosphonates on Fracture Healing Time and Changes in Bone Mass Density: A Meta-Analysis.

Authors:  Yongquan Gao; Xiaochen Liu; Yuan Gu; Deye Song; Muliang Ding; Lele Liao; Junjie Wang; Jiangdong Ni; Guangxu He
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-30       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.